Researchers have pinpointed five proteins associated with early-stage pancreatic cancer in bioengineered mice that were also found to be linked to a presymptomatic stage of the disease in humans. A commercial screening test that uses the five-biomarker panel could prove beneficial in detecting early-stage pancreatic cancer when used in tandem with a commercially available test that determines the levels of the biomarker CA19.9.

Related Summaries